The Trends Shaping Chinese Pharma Patent Litigation

As one of the world's largest drug consumer and manufacturing markets, China plays a pivotal role in global pharma patent strategies – and changes in the country's IP landscape can have profound commercial implications.

Nevertheless, clear and reliable insights into pharma patent litigation in China can be difficult to come by for IP strategists around the world. That's why we have put together this article examining the key trends shaping China's pharmaceutical IP landscape, including its four-year-old patent linkage system, invalidation actions, and patent enforcement. The insights it provides can help both generic and branded drug companies to avoid tactical pitfalls and make the best of strategic opportunities in China. Stakeholders, in generic or innovative medicine, may find both opportunities and challenges from these new trends in the pharmaceutical sector.